Noskin G A, Till M, Patterson B K, Clarke J T, Warren J R
Department of Medicine, (Division of Infectious Diseases), Northwestern University Medical School, Chicago, Illinois 60611.
J Infect Dis. 1991 Dec;164(6):1212-5. doi: 10.1093/infdis/164.6.1212.
In a retrospective analysis, patients with bacteremia due to Enterococcus faecalis with and without high-level gentamicin resistance (GRE; MIC greater than 2000 micrograms/ml) were compared. Bacteremic patients with GRE (n = 32) had significantly higher rates of nosocomial acquisition and bladder catheterization, longer hospitalizations, and more frequent prior treatment with cephalosporins than did bacteremic patients without high-level resistance (n = 19). Overall mortality was significantly associated with septic shock, high-risk source (intraabdominal, wound, respiratory tract, multiple, unknown), and polymicrobial bacteremia. Higher mortality was observed in GRE bacteremia (47%) than in bacteremia without high-level resistance (37%), but this difference was not statistically significant. For patients with monomicrobial bacteremia, low-risk source (genitourinary tract, intravascular), or treatment with antibiotics appropriate for the enterococcus, higher mortality with GRE bacteremia approached statistical significance. These results suggest that high-level resistance adversely affects survival with a pure E. faecalis bacteremia or low-risk bacteremic source. Also, response to antibiotic therapy may be diminished by high-level resistance.
在一项回顾性分析中,对粪肠球菌引起的菌血症患者进行了比较,这些患者分为有和没有高水平庆大霉素耐药(GRE;最低抑菌浓度大于2000微克/毫升)两组。有GRE的菌血症患者(n = 32)与没有高水平耐药的菌血症患者(n = 19)相比,医院获得性感染和膀胱插管的发生率显著更高,住院时间更长,先前使用头孢菌素治疗的频率更高。总体死亡率与感染性休克、高风险来源(腹腔内、伤口、呼吸道、多处、不明)和多种微生物菌血症显著相关。GRE菌血症患者的死亡率(47%)高于没有高水平耐药的菌血症患者(37%),但这种差异无统计学意义。对于单微生物菌血症、低风险来源(泌尿生殖道、血管内)或使用适合肠球菌的抗生素治疗的患者,GRE菌血症较高的死亡率接近统计学意义。这些结果表明,高水平耐药对单纯粪肠球菌菌血症或低风险菌血症来源的生存有不利影响。此外,高水平耐药可能会降低对抗生素治疗的反应。